These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12921517)

  • 1. Effect of tenofovir on didanosine absorption in patients with HIV.
    Pecora Fulco P; Kirian MA
    Ann Pharmacother; 2003 Sep; 37(9):1325-8. PubMed ID: 12921517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
    Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
    J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine.
    Kearney BP; Sayre JR; Flaherty JF; Chen SS; Kaul S; Cheng AK
    J Clin Pharmacol; 2005 Dec; 45(12):1360-7. PubMed ID: 16291710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir.
    Crane HM; Kestenbaum B; Harrington RD; Kitahata MM
    AIDS; 2007 Jul; 21(11):1431-9. PubMed ID: 17589189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen.
    Lowe SH; van Leeuwen E; Droste JA; van der Veen F; Reiss P; Lange JM; Burger DM; Repping S; Prins JM
    Ther Drug Monit; 2007 Oct; 29(5):566-70. PubMed ID: 17898645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tenofovir disoproxil fumarate.
    Gallant JE; Deresinski S
    Clin Infect Dis; 2003 Oct; 37(7):944-50. PubMed ID: 13130407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatitis with didanosine and tenofovir disoproxil fumarate [corrected].
    Blanchard JN; Wohlfeiler M; Canas A; King K; Lonergan JT
    Clin Infect Dis; 2003 Sep; 37(5):e57-62. PubMed ID: 12942419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [96-week treatment outcome confirms long term efficacy of tenofovir DF].
    Dtsch Med Wochenschr; 2003 May; 128(19):1074-5. PubMed ID: 12774796
    [No Abstract]   [Full Text] [Related]  

  • 9. Acute onset of pancreatitis with concomitant use of tenofovir and didanosine.
    Kirian MA; Higginson RT; Fulco PP
    Ann Pharmacother; 2004 Oct; 38(10):1660-3. PubMed ID: 15340130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily.
    Tung MY; Mandalia S; Bower M; Gazzard B; Nelson M
    HIV Med; 2005 May; 6(3):151-4. PubMed ID: 15876280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tenofovir and didanosine: a dangerous liaison.
    Waters L; Maitland D; Moyle GJ
    AIDS Read; 2005 Aug; 15(8):403-6, 413. PubMed ID: 16110555
    [No Abstract]   [Full Text] [Related]  

  • 12. Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.
    Barreiro P; Soriano V
    J Antimicrob Chemother; 2006 May; 57(5):806-9. PubMed ID: 16531427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tenofovir drug interactions: ddI and d4T.
    TreatmentUpdate; 2003; 15(2):7. PubMed ID: 12693363
    [No Abstract]   [Full Text] [Related]  

  • 14. Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients.
    Pruvost A; Negredo E; Benech H; Theodoro F; Puig J; Grau E; García E; Moltó J; Grassi J; Clotet B
    Antimicrob Agents Chemother; 2005 May; 49(5):1907-14. PubMed ID: 15855513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
    Bongiovanni M; Gianotti N; Chiesa E; Nasta P; Cicconi P; Capetti A; di Biagio A; Matti A; Tirelli V; Marconi P; de Luca A; Mussini C; Gatti F; Zaccarelli M; Abeli C; Torti C; Antinori A; Castagna A; d'Arminio Monforte A
    Infection; 2007 Dec; 35(6):451-6. PubMed ID: 18034204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible allergic cross-reaction to didanosine and tenofovir in an HIV-1-infected woman.
    Ripamonti D; Maggiolo F; Suter F
    AIDS; 2007 May; 21(8):1059-60. PubMed ID: 17457107
    [No Abstract]   [Full Text] [Related]  

  • 17. K65R, TAMs and tenofovir.
    Miller MD
    AIDS Rev; 2004; 6(1):22-33. PubMed ID: 15168738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comment on: suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.
    Anderson PL; Kakuda TN
    J Antimicrob Chemother; 2006 Jul; 58(1):220-1. PubMed ID: 16717052
    [No Abstract]   [Full Text] [Related]  

  • 19. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
    Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G
    Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine.
    Rollot F; Nazal EM; Chauvelot-Moachon L; Kélaïdi C; Daniel N; Saba M; Abad S; Blanche P
    Clin Infect Dis; 2003 Dec; 37(12):e174-6. PubMed ID: 14689363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.